Literature DB >> 19009231

GERD prevalence in migraine patients and the implication for acute migraine treatment.

Bozena J Katić1, Wendy Golden, Roger K Cady, X Henry Hu.   

Abstract

The objective of this study is to estimate the prevalence of gastroesophageal reflux disease (GERD) and heartburn in migraine patients and examine their use of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin-containing medications when treating acute migraine attacks. Responses from a web-based survey of migraine patients were matched to the same patient's responses on a general health survey. A total of 1,832 migraineurs (92.0%) were successfully matched. A total of 403 migraineurs (22.0%) reported having diagnosed GERD, 212 (11.6%) reported diagnosed heartburn, and 290 (15.8%) reported reflux symptoms but were undiagnosed. The most common prescription drugs used to treat migraines were triptans. First-line NSAID/aspirin medication use was 10.0% among diagnosed GERD and heartburn patients, 17.8% among undiagnosed patients, and 11.8% among GERD/heartburn-free migraineurs. In conclusion, almost half of migraineurs reported physician-diagnosed GERD and heartburn or symptoms of these conditions. Use of NSAID medications for migraine is fairly common among diagnosed GERD patients and more so for those with undiagnosed GERD symptoms. Physicians should minimize prescribing NSAIDs or NSAID-containing acute migraine medications in this population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009231      PMCID: PMC3451764          DOI: 10.1007/s10194-008-0083-1

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  41 in total

Review 1.  Gastroparesis: prevalence, clinical significance and treatment.

Authors:  M Horowitz; Y C Su; C K Rayner; K L Jones
Journal:  Can J Gastroenterol       Date:  2001-12       Impact factor: 3.522

Review 2.  New aspects of gastric adaptive relaxation, reflex after food intake for more food: involvement of capsaicin-sensitive sensory nerves and nitric oxide.

Authors:  T Arakawa; H Uno; T Fukuda; K Higuchi; K Kobayashi; T Kuroki
Journal:  J Smooth Muscle Res       Date:  1997-06

3.  Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.

Authors:  M Voutilainen; P Sipponen; J P Mecklin; M Juhola; M Färkkilä
Journal:  Digestion       Date:  2000       Impact factor: 3.216

4.  Reflux-triggered migraine headache originating from the upper gum/teeth.

Authors:  E L H Spierings
Journal:  Cephalalgia       Date:  2002-09       Impact factor: 6.292

5.  Acute migraine treatment with oral triptans and NSAIDs in a managed care population.

Authors:  Daisy S Ng-Mak; X Henry Hu; Ya-Ting Chen; Larry Ma
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

6.  How do people with gastro-oesophageal reflux disease perceive their disease? Results of a multinational survey.

Authors:  Philippe Ducrotté; Harley R Liker
Journal:  Curr Med Res Opin       Date:  2007-11       Impact factor: 2.580

Review 7.  Obesity, migraine, and chronic migraine: possible mechanisms of interaction.

Authors:  Marcelo E Bigal; Richard B Lipton; Philip R Holland; Peter J Goadsby
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability.

Authors:  Lisa Iversen; Philip C Hannaford; David J Godden; David Price
Journal:  Prim Care Respir J       Date:  2007-06

9.  Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study.

Authors:  A H Aamodt; L J Stovner; K Hagen; J-A Zwart
Journal:  Cephalalgia       Date:  2008-02       Impact factor: 6.292

Review 10.  The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.

Authors:  Loren Laine
Journal:  Semin Arthritis Rheum       Date:  2002-12       Impact factor: 5.532

View more
  8 in total

1.  Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran.

Authors:  Fahimeh Martami; Zeinab Ghorbani; Maryam Abolhasani; Mansoureh Togha; Alipasha Meysamie; Alireza Sharifi; Soodeh Razeghi Jahromi
Journal:  Neurol Sci       Date:  2017-10-11       Impact factor: 3.307

Review 2.  Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders.

Authors:  Elliot S Yu; Yasodara Priyadharsini S S; Thangam Venkatesan
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 3.  Chronic migraine plus medication overuse headache: two entities or not?

Authors:  Andrea Negro; Paolo Martelletti
Journal:  J Headache Pain       Date:  2011-09-22       Impact factor: 7.277

Review 4.  Gastrointestinal Headache; a Narrative Review.

Authors:  Majid T Noghani; Hossein Rezaeizadeh; Sayed Mohammad Baqer Fazljoo; Mansoor Keshavarz
Journal:  Emerg (Tehran)       Date:  2016-11

5.  Clinical Implications of Associations between Headache and Gastrointestinal Disorders: A Study Using the Hallym Smart Clinical Data Warehouse.

Authors:  Sang-Hwa Lee; Jae-June Lee; Youngsuk Kwon; Jong-Ho Kim; Jong-Hee Sohn
Journal:  Front Neurol       Date:  2017-10-03       Impact factor: 4.003

Review 6.  Gastrointestinal disorders associated with migraine: A comprehensive review.

Authors:  Carlos R Cámara-Lemarroy; Rene Rodriguez-Gutierrez; Roberto Monreal-Robles; Alejandro Marfil-Rivera
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

7.  Association of Gastrointestinal Functional Disorders and Migraine Headache: a Population Base Study.

Authors:  Kamran B Lankarani; Maryam Akbari; Reza Tabrizi
Journal:  Middle East J Dig Dis       Date:  2017-07

8.  Migraine and gastric disorders: Are they associated?

Authors:  Ahmad Hormati; Nayyereh Akbari; Ehsan Sharifipour; Seyyed Amir Hejazi; Fatemeh Jafari; Faezeh Alemi; Abolfaz Mohammadbeigi
Journal:  J Res Med Sci       Date:  2019-07-24       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.